<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149102">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159314</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00037146</org_study_id>
    <nct_id>NCT01159314</nct_id>
  </id_info>
  <brief_title>Baerveldt Plate Area Comparison (BPAC)</brief_title>
  <acronym>BPAC</acronym>
  <official_title>Baerveldt Plate Area Comparison (BPAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to compare the safety and effectiveness of two sizes of the
      Baerveldt glaucoma implant.

      A Baerveldt glaucoma implant is one of the most common types of glaucoma operations
      performed. This procedure works by providing a route by which fluid can drain out of the eye
      to decrease the intraocular pressure. The Baerveldt implant does this by placing a tube into
      the eye which shunts aqueous fluid to a silicone plate which is attached to the sclera
      (white portion of the eye). It is this plate that comes in two different sizes (250 square
      millimeters and 350 square millimeters).

      Earlier studies have shown that larger plate sizes produce lower eye pressures but that they
      may also result in more complications. While both Baerveldt devices are currently in use and
      have been shown to be safe and effective, it is unclear if one is superior to the other. The
      purpose of this study is to see if one size of device works better with fewer complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria (must have all of the following):

        1. Age over 18 Y N

        2. IOP &gt; 18 mm Hg and &lt; 40 mm Hg on medical therapy Y N

        3. Previous ocular surgery limited to cataract, corneal transplant, trabeculectomy,
           vitrectomy Y N

        4. Consent signed Y N

      Exclusion criteria (cannot have any of the following):

        1. Unwilling or unable to give consent, unwilling to accept randomization, or unable to Y
           N return for scheduled protocol visits

        2. Pregnant or nursing Y N

        3. NLP vision Y N

        4. Iris neovascularization or proliferative retinopathy Y N

        5. Iridocorneal endothelial syndrome Y N

        6. Epithelial or fibrous downgrowth Y N

        7. Chronic or recurrent uveitis Y N

        8. Steroid-induced glaucoma Y N

        9. Severe posterior blepharitis Y N

       10. Previous cyclodestructive procedure Y N

       11. Conjunctival scarring from prior ocular trauma or cicatrizing disease (e.g. Stevens
           Johnson syndrome, ocular pemphigoid) precluding Baerveldt implantation. Y N

       12. Functionally significant cataract Y N

       13. Need for Baerveldt implant combined with other ocular procedures (ie cataract surgery,
           Y N penetrating keratoplasty, or retinal surgery) or anticipated need for additional
           ocular surgery

       14. Prior glaucoma drainage device (tube) implant Y N

       15. Prior retinal surgery with remaining silicone oil Y N

       16. Prior scleral buckling procedures
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Annual follow-up visits</time_frame>
    <description>Visual acuity is an important outcome variable in the BPAC. Visual acuity is measured before pupil dilation, tonometry, gonioscopy, or any other technique that could affect vision. Two different techniques are used to measure visual acuity, including Snellen and ETDRS visual acuity testing. Visual acuity is measured at the Qualifying Assessment and at every follow-up visit. ETDRS visual acuity is required at the Qualifying Assessment and at the 1 year, 3 year, and 5 year follow-up visits</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Arm A - Baerveldt 250 mm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving Baerveldt 250 mm2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Baerveldt 350 mm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving Baerveldt 350 mm2</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Baerveldt Device surgical Procedure</intervention_name>
    <description>Implant surgery</description>
    <arm_group_label>Arm A - Baerveldt 250 mm2</arm_group_label>
    <arm_group_label>Arm B - Baerveldt 350 mm2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18

          -  IOP &gt; 18 mm Hg and &lt; 40 mm Hg on medical therapy

          -  Previous ocular surgery limited to (cataract, corneal transplant, trabeculectomy,
             vitrectomy)

          -  Consent signed

        Exclusion Criteria:

          -  Unwilling or unable to give consent, unwilling to accept randomization, or unable to
             return for scheduled protocol visits

          -  Pregnant or nursing

          -  NLP vision

          -  Iris neovascularization or proliferative retinopathy

          -  Epithelial or fibrous downgrowth

          -  Chronic or recurrent uveitis

          -  Steroid-induced glaucoma

          -  Severe posterior blepharitis

          -  Previous cyclodestructive procedure

          -  Conjunctival scarring from prior ocular trauma or cicatrizing disease (e.g. Stevens
             Johnson syndrome, ocular pemphigoid) precluding Baerveldt implantation.

          -  Functionally significant cataract

          -  Need for Baerveldt implant combined with other ocular procedures (ie cataract
             surgery,penetrating keratoplasty, or retinal surgery) or anticipated need for
             additional ocular surgery

          -  Prior glaucoma drainage device (tube) implant

          -  Prior retinal surgery with remaining silicone oil

          -  Prior scleral buckling procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Boland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Boland, MD, Ph.D.</last_name>
    <phone>410-502-4074</phone>
    <email>boland@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rhonda B Miller, COA</last_name>
    <phone>410-955-1779</phone>
    <email>rhbmiller@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California - Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817-2307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James D Brandt, MD</last_name>
      <phone>916-734-6969</phone>
      <email>jbrandt@uddavis.edu</email>
    </contact>
    <investigator>
      <last_name>James D Brandt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U. Miami/Bascom Palmer</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Wellik, MD</last_name>
      <email>SWellik@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Wellik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Boland, Md, Ph.D</last_name>
      <phone>410-502-4074</phone>
      <email>boland@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rhonda B Miller, COA</last_name>
      <phone>410-955-1779</phone>
      <email>rhbmiller@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Henry D Jampel, MD, MHS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harry Quigley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pradeep Ramulu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David S Friedman, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Serle, MD</last_name>
      <phone>212-241-8979</phone>
      <email>janet.serle@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Janet Serle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Myers, MD</last_name>
      <email>jmyers@willseye.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marlene Moster, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 30, 2016</lastchanged_date>
  <firstreceived_date>July 8, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Michael V. Boland, M.D., Ph.D</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>Baerveldt Implants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
